|
Mar 14
|
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
|
|
Mar 14
|
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
|
|
Mar 7
|
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
|
|
Mar 6
|
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
|
|
Feb 26
|
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
|
|
Feb 5
|
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
|
|
Jan 16
|
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
|
|
Jan 16
|
Vaxart, Inc. Announces Management Change
|
|
Dec 21
|
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
|
|
Nov 7
|
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely
|
|
Nov 3
|
Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Vaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business Updates
|
|
Nov 2
|
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
|
|
Nov 2
|
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
|
|
Aug 22
|
Strong week for Vaxart (NASDAQ:VXRT) shareholders doesn't alleviate pain of three-year loss
|
|
Jul 27
|
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
|
|
Jun 26
|
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
|
|
Jun 21
|
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
|